FIELD: biotechnology.
SUBSTANCE: disclosed are an antibody or an antigen-binding fragment thereof, which bind to B7H6, including immunoconjugates and pharmaceutical compositions. Also disclosed is a nucleic acid coding said antibody or antigen-binding fragment thereof, and a recombinant vector containing said nucleic acid and a recombinant cell for producing the antibody or its antigen-binding fragment. Invention also relates to use of antibodies and immunoconjugates according to the invention for preventing or treating a B7H6-mediated disease, as well as for diagnosing the presence of a B7H6-mediated disease in a subject.
EFFECT: antibody according to the present invention promotes binding of B7H6 to the NK-cell activation receptor NKp30, thus stimulating the anticancer function of NK-cells.
26 cl, 9 dwg, 2 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODIES AND THEIR APPLICATIONS | 2022 |
|
RU2821577C2 |
| PROPERDIN ANTIBODIES AND PRODUCTION THEREOF | 2021 |
|
RU2830308C1 |
| MONOCLONAL ANTIBODIES SPECIFIC TO PROTEIN RUSTICYANIN, AND USE OF ANTIBODIES FOR DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS | 2024 |
|
RU2823344C1 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| ANTIBODY AGAINST LAG-3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR PHARMACEUTICAL APPLICATION | 2017 |
|
RU2757813C2 |
| ANTI c-Met RECEPTOR PROTEIN ANTIBODIES | 2011 |
|
RU2608644C2 |
| MONOCLONAL ANTIBODY IC2 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817697C1 |
| BCMA-SPECIFIC CHIMERIC ANTIGEN RECEPTORS CONTAINING IL-6 SIGNALLING BLOCKER | 2023 |
|
RU2828294C1 |
| ANTIBODIES AGAINST HUMAN VSIG4 AND APPLICATION THEREOF | 2019 |
|
RU2776638C1 |
| ANTIBODY BOUND WITH CARBONIC ANHYDRASE, AND USE THEREOF | 2017 |
|
RU2727682C1 |
